BUSINESSMARKETWATCH
Major drugmaker loses $27 billion in market value after failed trial
A major drugmaker lost $27 billion in market value after a heart disease drug failed its Phase III trial, as announced by two companies on Thursday.
Related Signal
Adjacent reporting
- STAT+: AstraZeneca, Ionis report major trial failure with heart disease drug
- AstraZeneca stock dives 9% after heart drug trial misses target
- STAT+: Closely watched Pfizer lung cancer drug falls short in clinical trial
- Weight loss drug maker sinks 25% after new safety data spooks investors
- Cancer Drug Developer Erasca Sinks by Record 55% After Patient Death
- Zealand Pharma loses a fifth of its value as many users gave up taking weight-loss drug during trial